- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04412902
Predictors of Recurrence for High Risk Endometrial Cancer Patients
December 7, 2020 updated by: Sheng-Mou Hsiao, Far Eastern Memorial Hospital
This study will analyze whether there is any difference in recurrence and survival rates among the patients who received different adjuvant therapies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The incidence of endometrial cancer is gradually increasing nowaday.
The postoperative treatment of high-risk endometrial cancer is also inconsistent.
Besides, the recurrence of high-risk endometrial cancer is high.The investigators retrospective study will analyze the factors associated with recurrence of endometrial cancer, especially for different adjuvant therapies.
Study Type
Observational
Enrollment (Actual)
92
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Taipei
-
Banqiao, New Taipei, Taiwan, 22050
- Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
All high risk endometrial cancer patients
Description
Inclusion Criteria:
- All patients with high risk stage I endometrial cancer and all patients with stage II and stage III endometrial cancer and who underwent therapy in Far Eastern Memorial Hospital from 2009/01/01~2019/09/17.
Exclusion Criteria:
- Patients with stage I endometrial cancer do not have high risk factors.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Factors affecting overall survival
Time Frame: 10 years
|
Factors affecting overall survival
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Factors affecting progression-free survival
Time Frame: 10 years
|
Factors affecting progression-free survival
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2020
Primary Completion (Actual)
October 25, 2020
Study Completion (Actual)
November 25, 2020
Study Registration Dates
First Submitted
May 31, 2020
First Submitted That Met QC Criteria
May 31, 2020
First Posted (Actual)
June 2, 2020
Study Record Updates
Last Update Posted (Actual)
December 9, 2020
Last Update Submitted That Met QC Criteria
December 7, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 109053-E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-risk Endometrial Cancer
-
Xiaojun ChenChongqing University Cancer Hospital; Sun Yat-sen University; Fudan University; Tongji Hospital and other collaboratorsRecruitingPrognosis | Middle-high Risk Endometrial Cancer | Sentinel Lymph Node SamplingChina
-
Prisma Health-UpstateRecruiting
-
University of Texas Southwestern Medical CenterCompletedHigh-Risk Cancer
-
Memorial Sloan Kettering Cancer CenterCompletedCancer Survivors | Statin Use Among High Risk SurvivorsUnited States
-
European Institute of OncologyTerminated
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
George Washington UniversityUniversity of North Carolina, Chapel Hill; Aga Khan University; Kenya Medical... and other collaboratorsRecruitingPregnancy, High RiskPakistan, Ghana, Kenya, India, Zambia
-
George Washington UniversityRecruitingPregnancy, High RiskPakistan, Kenya, Zambia
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia
-
University of AarhusCopenhagen University Hospital, HvidovreCompletedAn Adapted Mindfulness-based Stress Reduction Program for Psycho-socially Vulnerable Pregnant Women.Pregnancy, High RiskDenmark
Clinical Trials on adjuvant therapy
-
Tao OUYANGActive, not recruiting
-
The Central and Eastern European Gynecologic Oncology...RecruitingCervical CancerCzechia
-
PT. Prodia Stem Cell IndonesiaRecruitingNasopharyngeal CancerIndonesia
-
Asan Medical CenterUnknown
-
Medical Research CouncilCompletedHead and Neck Cancer | Non-melanomatous Skin CancerUnited Kingdom
-
European Organisation for Research and Treatment...UnknownBrain and Central Nervous System TumorsSwitzerland
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Genzyme, a Sanofi CompanyCompleted
-
Center of Personalized Medicine, PirogovaI.M. Sechenov First Moscow State Medical University; Center for New Medical...UnknownBreast Cancer-specific SurvivalRussian Federation
-
Peking University Third HospitalNot yet recruitingStereotactic Body Radiation TherapyChina